Dr. Steven R. Jones, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2361 Murray Holladay Rd, Holladay, UT 84117 Phone: 801-277-8512 Fax: 801-277-8562 |
Thomas Bullock Simon, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 6405 S 3000 E Ste 300, Holladay, UT 84121 Phone: 801-266-3113 Fax: 801-931-2166 |
News Archive
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
Hydrogen Advertising has partnered with the Greater Washington Chapter of the National MS Society to handle creative duties for the organization on a pro bono basis. The agency will build upon the success of the National MS Society's recent "Why Here?" campaign, helping further regional awareness and understanding of this debilitating disease.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has determined that additional time is required to complete the review of the biologics license application (BLA) for ipilimumab in pre-treated advanced melanoma, and has moved its decision date from December 25, 2010 to March 26, 2011.
Mount Sinai Medical Center in Miami Beach, Florida announced its participation in the Medtronic CoreValve U.S. Clinical Trial, which will evaluate a new, non-surgical alternative to open-heart surgery for patients with severe aortic stenosis. Mount Sinai is now among a select number of leading hospitals across the U.S. to participate in this trial.
› Verified 7 days ago